Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | VCP | P55072 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HPRT1 | P00492 | 6/20 | 0.39 |
| ▸ | PNP | P00491 | 6/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | HBB | P68871 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Penciclovir SCHEMBL3494 | 0.93 | TK1 (0.49) | GAAKMT2ATK1BLMMEN1 | |
| Penciclovir SCHEMBL4240103 | 0.88 | HPRT1 (0.47) | KMT2ATK1BLMMEN1ALDH1A1 | |
| SCHEMBL133681 | 0.88 | TK1 (0.43) | GAAKMT2ATK1BLMMEN1 | |
| Penciclovir SCHEMBL454089 | 0.88 | HPRT1 (0.47) | KMT2ATK1BLMMEN1ALDH1A1 | |
| SCHEMBL15045959 | 0.88 | GAA (0.43) | GAAKMT2ATK1BLMMEN1 | |
| SCHEMBL15046000 | 0.88 | GAA (0.42) | GAAKMT2ATK1BLMMEN1 | |
| Water SCHEMBL15532449 | 0.87 | TK1 (0.42) | GAAKMT2ATK1BLMMEN1 | |
| SCHEMBL15257623 | 0.86 | KMT2A (0.42) | GAAKMT2ATK1BLMMEN1 | |
| Penciclovir SCHEMBL15568622 | 0.83 | HPRT1 (0.42) | KMT2ATK1BLMMEN1ALDH1A1 | |
| Tiviciclovir SCHEMBL15531845 | 0.83 | BLM (0.45) | GAAKMT2ATK1BLMMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150080417-A1 | THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS | G2L TOUCH, INC. | 2015-03-19 | — | — | US | disclosed |
| US-8853223-B2 | Therapeutic composition to treat lesions caused by herpes simplex virus | G2L TOUCH, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20120071498-A1 | THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS | G2L TOUCH, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20110065655-A1 | THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS | GK VENTURES, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065655-A1 | THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS | G6PD, DUS2, MVD | GAA 108/4885KMT2A 795/4885TK1 39/4885 |
| US-20120071498-A1 | THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS | EXOSC9, PSEN1, PSEN2 | GAA 1179/4885KMT2A 595/4885TK1 31/4885 |
| US-20150080417-A1 | THERAPEUTIC COMPOSITION TO TREAT LESIONS CAUSED BY HERPES SIMPLEX VIRUS | EXOSC9, PSEN1, PSEN2 | GAA 1179/4885KMT2A 595/4885TK1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.